Core Viewpoint - RenovoRx, Inc. is set to present at H.C. Wainwright's 26th Annual Global Investment Conference, highlighting its advancements in precision oncology therapies and ongoing clinical trials for pancreatic cancer treatment [1][2]. Company Overview - RenovoRx is a clinical-stage biopharmaceutical company focused on developing novel precision oncology therapies using a local drug-delivery platform aimed at improving therapeutic outcomes for cancer patients [7]. - The company's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to deliver chemotherapy directly to tumors while minimizing systemic toxicity [7][8]. Clinical Trials - The ongoing Phase III TIGeR-PaC clinical trial is evaluating the TAMP™ therapy platform for treating Locally Advanced Pancreatic Cancer (LAPC) [5][6]. - The primary endpoint of the trial is a 6-month Overall Survival benefit, with secondary endpoints including reduced side effects compared to standard care [6]. - The first interim analysis was completed in March 2023, with a recommendation to continue the study, and the second interim analysis is expected in late 2024 or early 2025 [6]. Recent Developments - Shaun Bagai, CEO of RenovoRx, will discuss recent corporate achievements and the exploration of new commercial business development opportunities at the upcoming conference [2][3]. - The company appointed Ryan Witt as Senior Vice President of Corporate Strategy and Partnerships in June 2024 to enhance its business development efforts [2]. Product Information - RenovoRx's first product candidate utilizing the TAMP technology involves the intra-arterial administration of gemcitabine HCl via the FDA-cleared RenovoCath® device [5][7]. - RenovoCath is indicated for temporary vessel occlusion in various applications, including arteriography and chemotherapeutic drug infusion [2][7].
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York